Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-03-20 | CHRS | Coherus Biosciences, Inc. | Viret Jean-Frederic | CFO | S - Sale | $14.92 | -3,000 | 13,185 | -19% | -$44,762 | ||||||
| D | 2019-03-21 | FATE | Fate Therapeutics Inc | Wolchko J Scott | Pres, CEO | S - Sale+OE | $17.61 | -20,000 | 374,881 | -5% | -$352,160 | |||||
| A | 2019-01-07 | NITE | Nightstar Therapeutics Plc | Fellows David A | CEO | S - Sale | $12.98 | -8,733 | 626,395 | -1% | -$113,361 | |||||
| D | 2019-03-20 | GILD | Gilead Sciences Inc | Cogan John Francis | Dir | S - Sale+OE | $65.07 | -2,700 | 54,860 | -5% | -$175,689 | |||||
| D | 2019-03-19 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $58.53 | -15,000 | 246,000 | -6% | -$877,989 | |||||
| A | 2019-03-19 | APTO | Aptose Biosciences Inc. | Platzer Erich | Dir | P - Purchase | $2.19 | +20,000 | 135,000 | +17% | +$43,805 | |||||
| D | 2019-03-18 | MNTA | Momenta Pharmaceuticals Inc | Downey Bruce | Dir | S - Sale+OE | $14.51 | -13,000 | 28,234 | -32% | -$188,630 | |||||
| D | 2019-03-18 | EDIT | Editas Medicine, Inc. | Myer Vickesh | CTO | S - Sale+OE | $24.50 | -3,000 | 0 | -100% | -$73,500 | |||||
2019-03-19 | APTO | Aptose Biosciences Inc. | Platzer Erich | Dir | S - Sale | $2.19 | -20,000 | 135,000 | -13% | -$43,805 | ||||||
2019-03-18 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale | $59.63 | -14,550 | 215,107 | -6% | -$867,633 | ||||||
| D | 2019-03-15 | RUBY | Rubius Therapeutics, Inc. | Carpenter Christopher L. | Chief Medical Officer | S - Sale+OE | $15.84 | -48,000 | 34,843 | -58% | -$760,114 | |||||
2019-03-18 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale | $14.20 | -29,167 | 112,166 | -21% | -$414,171 | ||||||
2019-03-15 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale | $13.92 | -10,000 | 77,566 | -11% | -$139,200 | ||||||
2019-03-15 | ATRA | Atara Biotherapeutics, Inc. | Marcus Joel S | Dir | S - Sale | $38.25 | -20,000 | 899,855 | -2% | -$765,000 | ||||||
| D | 2019-03-18 | BIIB | Biogen Inc. | Pangia Robert W | Dir | S - Sale+OE | $328.55 | -6,114 | 18,587 | -25% | -$2,008,755 | |||||
2019-03-19 | HEB | Hemispherx Biopharma Inc | Equels Thomas K. | Exec. Vice COB, CEO, Pres | P - Purchase | $0.18 | +13,400 | 811,707 | +2% | +$2,352 | ||||||
| D | 2019-03-15 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | EVP, CFO | S - Sale+OE | $10.00 | -5,000 | 25,512 | -16% | -$50,000 | |||||
| D | 2019-03-14 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale+OE | $25.01 | -1,000 | 213,990 | 0% | -$25,010 | |||||
| M | 2019-03-14 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $39.48 | -7,800 | 659,980 | -1% | -$307,953 | |||||
2019-03-14 | ASRT | Assertio Therapeutics, Inc | Higgins Arthur J | Dir, Pres, CEO | P - Purchase | $4.17 | +10,000 | 190,879 | +6% | +$41,700 | ||||||
2019-03-14 | APTO | Aptose Biosciences Inc. | Rice William G. | Chair, Pres, CEO | P - Purchase | $1.90 | +10,000 | 143,014 | +8% | +$18,993 | ||||||
| D | 2019-03-13 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $146.41 | -3,101 | 31,616 | -9% | -$454,005 | |||||
2019-03-14 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale | $0.28 | -60,000 | 76,530 | -44% | -$16,500 | ||||||
2019-03-13 | APTO | Aptose Biosciences Inc. | Chow Gregory K. | SVP, CFO | P - Purchase | $1.75 | +15,000 | 127,014 | +13% | +$26,322 | ||||||
2019-03-12 | VYGR | Voyager Therapeutics, Inc. | Neurocrine Biosciences Inc | 10% | P - Purchase | $11.96 | +4,179,728 | 4,179,728 | New | +$49,999,996 | ||||||
2019-03-12 | BCRX | Biocryst Pharmaceuticals Inc | Aselage Steve | Dir | P - Purchase | $8.30 | +2,000 | 2,000 | New | +$16,600 | ||||||
| M | 2019-03-11 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COO, Secretary | S - Sale | $22.58 | -7,500 | 670,827 | -1% | -$169,313 | |||||
| D | 2019-03-11 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Strategy Officer | S - Sale+OE | $139.80 | -1,500 | 40,921 | -4% | -$209,698 | |||||
| D | 2019-03-08 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $69.19 | -20,148 | 732,613 | -3% | -$1,394,094 | |||||
| D | 2019-03-08 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | Chief Technical Officer | S - Sale+OE | $68.72 | -8,000 | 177,329 | -4% | -$549,746 | |||||
2019-03-11 | VCEL | Vericel Corp | Michel Gerard J | CFO, VP, Corp. Development | S - Sale | $20.02 | -10,000 | 122,249 | -8% | -$200,235 | ||||||
| D | 2019-03-06 | AMGN | Amgen Inc | Sugar Ronald D | Dir | S - Sale+OE | $188.88 | -2,000 | 12,988 | -13% | -$377,760 | |||||
2019-03-08 | CDTX | Cidara Therapeutics, Inc. | Abdollahian Neil | Chief Business Officer | S - Sale | $2.44 | -2,300 | 30,472 | -7% | -$5,612 | ||||||
2019-03-07 | CDTX | Cidara Therapeutics, Inc. | Daruwala Paul | COO | S - Sale | $2.55 | -2,240 | 49,567 | -4% | -$5,714 | ||||||
| D | 2019-03-05 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $147.71 | -1,800 | 32,592 | -5% | -$265,879 | |||||
2019-03-05 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $60.01 | -3,068 | 239,215 | -1% | -$184,111 | ||||||
2019-03-05 | EDIT | Editas Medicine, Inc. | Hopfield Jessica | Dir | P - Purchase | $23.94 | +10,200 | 16,900 | +152% | +$244,188 | ||||||
2019-03-04 | SGEN | Seattle Genetics Inc /wa | Simpson Todd E | CFO | S - Sale | $75.00 | -10,000 | 184,280 | -5% | -$750,000 | ||||||
| D | 2019-03-04 | KLDO | Kaleido Biosciences, Inc. | Flagship Ventures Fund V General Partner LLC | Dir, 10% | P - Purchase | $15.00 | +933,333 | 4,744,305 | +24% | +$13,999,995 | |||||
| D | 2019-03-04 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $155.77 | -4,910 | 31,616 | -13% | -$764,832 | |||||
| D | 2019-03-01 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | EVP, CFO | S - Sale+OE | $10.00 | -5,000 | 25,512 | -16% | -$50,000 | |||||
| D | 2019-03-01 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Tech. Operations Officer | S - Sale+OE | $36.13 | -1,500 | 47,146 | -3% | -$54,202 | |||||
| DM | 2019-03-01 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale+OE | $22.17 | -17,500 | 214,490 | -8% | -$388,000 | |||||
| M | 2019-03-01 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $22.18 | -18,333 | 2,628,476 | -1% | -$406,601 | |||||
| M | 2019-03-01 | CRSP | Crispr Therapeutics AG | Novak Rodger | Pres | S - Sale | $40.40 | -85,220 | 948,007 | -8% | -$3,443,037 | |||||
2019-03-05 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale | $58.50 | -13,000 | 229,657 | -5% | -$760,500 | ||||||
2019-03-05 | RGEN | Repligen Corp | Kuriyel Ralf | SVP, R, D | S - Sale | $58.53 | -2,240 | 18,803 | -11% | -$131,107 | ||||||
2019-03-05 | RGEN | Repligen Corp | Snodgres Jon | CFO | S - Sale | $58.52 | -2,645 | 27,001 | -9% | -$154,785 | ||||||
| D | 2019-03-01 | MGTX | Meiragtx Holdings Plc | Perceptive Life Sciences Master Fund Ltd | 10% | P - Purchase | $13.80 | +1,304,348 | 6,007,746 | +28% | +$18,000,002 | |||||
| D | 2019-03-01 | FATE | Fate Therapeutics Inc | Tahl Cindy | GC, Secretary | S - Sale+OE | $16.15 | -25,000 | 90,418 | -22% | -$403,698 | |||||
| D | 2019-02-28 | KLDO | Kaleido Biosciences, Inc. | Bonney Michael W | Exec Chair | P - Purchase | $13.97 | +71,520 | 1,651,196 | +5% | +$999,493 | |||||
| D | 2019-02-28 | RGEN | Repligen Corp | Snodgres Jon | CFO | S - Sale+OE | $58.88 | -1,875 | 24,946 | -7% | -$110,400 | |||||
| D | 2019-02-28 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale+OE | $59.01 | -7,475 | 242,657 | -3% | -$441,100 | |||||
| D | 2019-02-28 | RGEN | Repligen Corp | Kuriyel Ralf | SVP, R, D | S - Sale+OE | $59.16 | -185 | 16,343 | -1% | -$10,945 | |||||
2019-02-28 | BLUE | Bluebird Bio, Inc. | Wentworth Kory James | Principal Accounting Officer | S - Sale | $151.71 | -51 | 6,695 | -1% | -$7,737 | ||||||
| D | 2019-02-28 | VCEL | Vericel Corp | Gilman Steven C | Dir | S - Sale+OE | $18.02 | -7,500 | 0 | -100% | -$135,129 | |||||
| M | 2019-02-27 | NSTG | Nanostring Technologies Inc | Allen Mary Tedd | SVP, Operations | S - Sale | $25.16 | -11,250 | 13,946 | -45% | -$283,061 | |||||
2019-02-27 | ONCE | Spark Therapeutics, Inc. | Children'S Hospital of Philadelphia Foundation | 10% | S - Sale | $113.00 | -2,000,000 | 1,954,957 | -51% | -$226,000,000 | ||||||
| M | 2019-02-27 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $36.14 | -7,800 | 667,780 | -1% | -$281,891 | |||||
| D | 2019-02-28 | ATRA | Atara Biotherapeutics, Inc. | Marcus Joel S | Dir | S - Sale+OE | $36.07 | -62,590 | 919,855 | -6% | -$2,257,621 | |||||
| D | 2019-02-25 | RGNX | Regenxbio Inc. | Simpson Curran | SVP, Product Development, CTO | S - Sale+OE | $54.05 | -5,300 | 39,500 | -12% | -$286,465 | |||||
| D | 2019-02-25 | BLUE | Bluebird Bio, Inc. | Cole Jason | COO and | S - Sale+OE | $150.24 | -6,248 | 26,444 | -19% | -$938,698 | |||||
2019-02-25 | BLUE | Bluebird Bio, Inc. | Wentworth Kory James | Principal Accounting Officer | S - Sale | $150.00 | -208 | 6,746 | -3% | -$31,201 | ||||||
| D | 2019-02-25 | BOLD | Audentes Therapeutics, Inc. | Prasad Suyash | SVP, Chief Med Officer | S - Sale+OE | $30.06 | -10,000 | 18,236 | -35% | -$300,553 | |||||
| D | 2019-02-25 | BOLD | Audentes Therapeutics, Inc. | Patterson Matthew R | CEO | S - Sale+OE | $30.00 | -21,000 | 290,514 | -7% | -$630,000 | |||||
2019-02-25 | CRSP | Crispr Therapeutics AG | Novak Rodger | Pres | S - Sale | $40.00 | -14,780 | 1,033,227 | -1% | -$591,233 | ||||||
| D | 2019-02-25 | FATE | Fate Therapeutics Inc | Tahl Cindy | GC, Secretary | S - Sale+OE | $16.07 | -25,000 | 90,418 | -22% | -$401,820 | |||||
2019-02-22 | ACOR | Acorda Therapeutics Inc | Sabella Lauren M | Chief Commercial Officer | S - Sale | $13.18 | -761 | 5,092 | -13% | -$10,028 | ||||||
2019-02-22 | ACOR | Acorda Therapeutics Inc | Lawrence David | Chief, Bus. Ops, PAO | S - Sale | $13.18 | -761 | 5,092 | -13% | -$10,028 | ||||||
| D | 2019-02-22 | AMRN | Amarin Corp Plcuk | Van Heek G Jan | Dir | S - Sale+OE | $20.02 | -203,382 | 14,168 | -93% | -$4,071,423 | |||||
| D | 2019-02-20 | EDIT | Editas Medicine, Inc. | Myer Vickesh | CTO | S - Sale+OE | $20.42 | -3,000 | 0 | -100% | -$61,260 | |||||
2019-02-20 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale | $14.08 | -1,435 | 578,194 | 0% | -$20,205 | ||||||
2019-02-20 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Chief Business Officer | S - Sale | $14.05 | -351 | 125,883 | 0% | -$4,932 | ||||||
2019-02-20 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale | $14.05 | -351 | 87,566 | 0% | -$4,932 | ||||||
| D | 2019-02-19 | TCRR | Tcr2 Therapeutics Inc. | Ubs Oncology Impact Fund L.P. | 10% | P - Purchase | $15.00 | +666,667 | 3,370,982 | +25% | +$10,000,005 | |||||
| D | 2019-02-19 | TCRR | Tcr2 Therapeutics Inc. | Mpm Sunstates Fund, L.P. | 10% | P - Purchase | $15.00 | +706,666 | 4,050,865 | +21% | +$10,599,990 | |||||
| D | 2019-02-19 | TCRR | Tcr2 Therapeutics Inc. | Mpm Bioventures 2014, L.P. | 10% | P - Purchase | $15.00 | +706,666 | 4,050,865 | +21% | +$10,599,990 | |||||
| D | 2019-02-19 | TCRR | Tcr2 Therapeutics Inc. | Jovan-Embiricos Morana | Dir, 10% | P - Purchase | $15.00 | +666,667 | 536,962 | -514% | +$10,000,005 | |||||
| D | 2019-02-19 | TCRR | Tcr2 Therapeutics Inc. | Upnorth Investment Ltd | 10% | P - Purchase | $15.00 | +200,000 | 2,137,419 | +10% | +$3,000,000 | |||||
| D | 2019-02-19 | TCRR | Tcr2 Therapeutics Inc. | Gadicke Ansbert | Dir, 10% | P - Purchase | $15.00 | +1,373,333 | 1,569,235 | +701% | +$20,599,995 | |||||
| M | 2019-02-19 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale | $13.64 | -8,780 | 141,333 | -6% | -$119,757 | |||||
| A | 2019-02-03 | HALO | Halozyme Therapeutics Inc | Chondros Dimitrios | SVP, Chief Medical Officer | S - Sale | $16.41 | -2,536 | 31,566 | -7% | -$41,616 | |||||
| D | 2019-02-19 | GILD | Gilead Sciences Inc | Wilson Gayle E | Dir | S - Sale+OE | $67.08 | -19,068 | 124,499 | -13% | -$1,279,074 | |||||
2019-02-15 | ATRA | Atara Biotherapeutics, Inc. | Haqq Christopher | EVP, R, D, Chief Scientific Of | S - Sale | $39.59 | -775 | 291,943 | 0% | -$30,682 | ||||||
| D | 2019-02-15 | ATRA | Atara Biotherapeutics, Inc. | Porter Derrell | SVP, Head of Global Commercial | S - Sale+OE | $40.00 | -5,909 | 21,688 | -21% | -$236,360 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Sonsini Peter W. | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Sandell Scott D | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Mott David M | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Makower Joshua | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Makhzoumi Mohamad | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Florence Anthony A. Jr. | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Chang Carmen | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Behbahani Ali | Dir, 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Baskett Forest | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | Barris Peter J | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
| D | 2019-02-14 | GNCA | Genocea Biosciences, Inc. | New Enterprise Associates 16, L.P. | 10% | P - Purchase | $0.47 | +9,948,269 | 34,948,269 | +40% | +$4,688,619 | |||||
2019-02-13 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale | $12.67 | -16,875 | 579,629 | -3% | -$213,806 | ||||||
2019-02-14 | MNTA | Momenta Pharmaceuticals Inc | Robertson Michelle | CFO | S - Sale | $13.10 | -703 | 11,526 | -6% | -$9,209 | ||||||
2019-02-14 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale | $13.10 | -4,449 | 76,001 | -6% | -$58,282 | ||||||
2019-02-14 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Chief Business Officer | S - Sale | $13.10 | -4,450 | 126,234 | -3% | -$58,295 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |